TABLE OF CONTENT

Section I Introduction

1.	**Introduction**	**1**
1.1.	Diabetes Mellitus	1
1.1.1.	Diabetes: A Local and Global Epidemic	1
1.1.2.	Definition	1
1.2.	Oral Antidiabetic Agents	4
1.3.	Pharmaceutical Dosage Form Development	6
1.3.1.	Commercial Compulsions	7
1.3.2.	Technological Advances	7
1.3.3.	Terminology	8
1.3.4.	Rationale of sustained/controlled drug delivery	8
1.3.5.	Most Preferred Route of Administration - Oral (Tablets)	10
1.3.6.	Pharmacokinetic/Pharmacodynamic basis of controlled /sustained drug delivery	11
1.3.6.1.	Biological Factors Influencing Oral SR Dosage Form Design	11
1.3.6.1.1.	Biological Half-life	11
1.3.6.1.2.	Absorption	12
1.3.6.1.3.	Metabolism	12
1.3.6.2.	Physicochemical Factors Influencing Oral SR Dosage Form Design	13
1.3.6.2.1.	Dose Size	13
1.3.6.2.2.	Aqueous Solubility, Ionization and pKa	13
1.3.6.2.3.	Partition Coefficient	14
1.3.6.2.4.	Stability	14
1.3.7.	Pros And Cons of Controlled Release Dosage Forms	15
1.3.8.	Classification of Controlled Release Dosage Forms	15
1.3.9.	Matrix Systems - First Choice of Manufacturer	17
1.3.10.	Direct Compression - Scientific & Economic Appeal	18
1.3.10.1.	Advantages of Direct Compression	20
1.3.10.2.	Limitations of Direct Compression	21
1.4.	Aims and Objectives	22
1.5.	References	23
2.	**Polymers & Excipients**	**27**
2.1.	General Considerations for Direct Compression Excipients-Fillers-Binders	27
2.2.	Spray-Dried Lactose	27
2.2.1.	Introduction	27
2.2.2.	Manufacturing	28
2.2.3.	Functional Properties	28
2.2.4.	Pharmaceutical Application	29
2.3.	Pregelatinized Starch	29
2.3.1.	Introduction	29
2.3.2.	Manufacturing	30

2.3.3.	Multi-Functionality	31
2.3.3.1.	Flow-Aid	31
2.3.3.2.	Self-Lubricant	31
2.3.3.3.	Wet Granulation	31
2.3.3.4.	Direct Compaction	32
2.3.3.5.	HPMC Matrices with Starch	32
2.3.3.6.	Low Dose Medicines	33
2.3.3.7.	Moisture of Sensitive Actives	33
2.3.3.8.	Super-Disintegrants	34
2.3.4.	Applications	34
2.4.	Microcrystalline cellulose (MCC)	35
2.4.1.	Introduction	35
2.4.2.	Manufacturing	36
2.4.3.	Properties and Functionality	36
2.4.4.	Applications	38
2.5.	Sodium Alginate	40
2.5.1.	Introduction	40
2.5.2.	Manufacturing / Processing	40
2.5.3.	Chemistry	41
2.5.4.	Functionality and Rheology	42
2.6.	Carrageenans	44
2.6.1.	Introduction	44
2.6.2.	Manufacturing	45
2.6.3.	Functionality and Rheology	47
2.6.3.1.	Factors influencing gelling	49
2.6.4.	Pharmaceutical Applications	49
2.7.	Carbopol	50
2.7.1.	Introduction	50
2.7.1.1.	Nomenclature:	50
2.7.1.2.	Chemistry	50
2.7.2.	Manufacturing:	52
2.7.3.	Applications	53
2.7.4.	Polymer swelling & Performance Mechanism	54
2.8.	Guar Gum	56
2.8.1.	Introduction	56
2.8.2.	Structural Formula	57
2.8.3.	Manufacturing	57
2.8.4.	Physicochemical Prperties	58
2.8.5.	Pharmaceutical Applications	58
2.9.	Xanthan Gum	59
2.9.1.	Introduction	59
2.9.2.	Xanthan Structual Unit	60
2.9.3.	Functionality	61
2.9.4.	Physicochemical Properties of Xanthan	62
2.9.5.	Pharmaceutical Applications	63
2.10.	HPMC / Hypromellose	63
2.10.1.	Introduction	63
2.10.2.	Nomenclature for Methocel Products	64
2.10.3.	Polymer Structure and manufacturing	65
2.10.4.	Polymer Properties	65

2.10.4.1.	Molecular Weight and Viscosity	65
2.10.4.2.	Hydration and Erosion Rates	66
2.10.5.	Factors affecting the drug release	67
2.10.5.1.	Hydrophilic Matrix Systems	67
2.10.5.2.	Selection of Methocel Polymers Type	67
2.10.5.3.	Polymer Level	69
2.10.5.4.	Effect of Particle Size	69
2.10.5.5.	Effects of Binders and Lubricants on Direct Compression	70
2.10.6.	Advantages of Methocel	71
2.10.6.1.	Simple Formulations	71
2.10.6.2.	Manufacture of matrix tablets	71
2.11.	Ethylcellulose	72
2.11.1.	Introduction	72
2.11.2.	Manufacturing	72
2.11.3.	Physicochemical Properties	73
2.11.4.	Pharmaceutical Applications	73
2.12.	Polymethacrylates	74
2.12.1.	Introduction	74
2.12.2.	Structural Formula	75
2.12.3.	Mechanism of drug release from Eudragit	77
2.12.4.	Pharmaceutical Applications	77
2.13.	References	79
3.	**Literature Survey**	**87**
3.1.	References	100

Section II Experimental Work

4.	**Experimental Work**	**105**
4.1.	Materials	105
4.1.1.	Drugs and Formulations	105
4.1.2.	Polymers and excipients	105
4.1.3.	Chemicals and reagents	106
4.1.4.	Equipments/Instruments	106
4.2.	Analytical Method Development	106
4.2.1.	Estimation of Glipizide (Spectroscopic Method)	107
4.2.2.	Estimation of Nateglinide (Spectroscopic Method)	107
4.2.3.	Estimation of Glipizide (HPLC Method)	107
4.2.3.1.	Equipment and Chromatographic Conditions	107
4.2.3.2.	Preparation of Standard Solutions	108
4.2.3.3.	Optimization of Chromatographic Separation Conditions	108
4.2.3.4.	Estimation of Glipizide from Rabbit Plasma	109
4.2.3.5.	Validation of Proposed Method	110
4.2.3.5.1.	Calibration Curve (Linearity)	110
4.2.3.5.2.	Accuracy and Precision	110
4.2.3.5.3.	Sensitivity	111
4.2.3.5.4.	Selectivity	111
4.2.3.5.5.	Stability	111

4.2.3.5.6.	Extraction Efficiency	111
4.2.3.6.	Pharmacokinetic Analysis of Glipizide from Rabbits	112
4.2.4.	Estimation of Nateglinide (HPLC Method)	113
4.2.4.1.	Equipment and Chromatographic Conditions	113
4.2.4.2.	Preparation of Standard Solutions	113
4.2.4.3.	Optimization of Chromatographic Separation Conditions	114
4.2.4.4.	Estimation of Nateglinide from Rabbit Plasma	114
4.2.4.5.	Validation of Proposed Method	114
4.2.4.6.	Pharmacokinetic Analysis of Nateglinide from Rabbits	114
4.3.	Experimental Work	115
4.3.1.	Drug–Excipient Interaction Studies	115
4.3.2.	Preparation & Characterization of Physical Mixture	115
4.3.3.	Preparation & Characterization of Matrix Tablets	116
4.3.4.	Glipizide Matrices	116
4.3.4.1.	HPMC-MCC-Starch Matrices	118
4.3.4.1.1.	3^2 Full Factorial Experimental Design & Response Surface	118
4.3.4.2.	MCC-Alginate & MCC-Glyceryl Behenate Matrices	119
4.3.4.3.	EC-HPMC, Guar Gum & Xanthan Gum Matrices	120
4.3.4.4.	Carbopol Matrices	121
4.3.4.5.	Carrageenan Matrices	122
4.3.4.6.	Eudragit Matrices	123
4.3.4.7.	Sodium Alginate Matrices	123
4.3.5.	Nateglinide Matrices	124
4.3.5.1.	HPMC-MCC-Starch Matrices	124
4.3.5.2.	Ethyl Cellulose & Carbopol Matrices	125
4.3.5.3.	Xanthan Gum Matrices	125
4.3.5.4.	Alginate-Chitosan & Eudragit-HPMC Matrices	126
4.4.	In Vitro Study	126
4.4.1.	Assay of Glipizide Content of Tablet	126
4.4.2.	Drug Release Studies	127
4.4.3.	Curve Fitting and Release Kinetics	128
4.4.4.	Swelling Study	129
4.4.5.	Scanning Electron Microscopy (SEM)	130
4.4.6.	Stability Study	130
4.5.	In Vivo Study	131
4.5.1.	Drug Absorption Study in Rabbits	131
4.5.1.1.	Animal Housing and Handling	131
4.5.1.2.	IVIVC Development using Slow, Medium, & Fast Release Rate Formulations of HPMC-MCC Matrix	131
4.5.1.3.	Establishment of IVIVC for Glytop® 2.5 SR, M-25, M-75, M-120, Natelide® 60 (Immediate Release Tablet), J-11, and J-21	132
4.5.2.	Pharmacokinetic Analysis	132
4.5.3.	Establishment of In Vitro-In Vivo Correlation (IVIVC)	133
4.5.3.1.	Internal Validation of IVIVC	133
4.6.	References	134

Section III Results & Discussion

5.	**Results & Discussion**	**137**
5.1.	Characterization of Physical Mixtures & Matrix Tablets	137
5.1.1.	Drug-Excipient Interaction Studies	137
5.1.2.	Characterization of Physical Mixture	139
5.1.3.	Characterization of Matrix Tablets	140
5.2.	Analytical Method development	140
5.2.1.	Estimation of Glipizide (Spectroscopic Method)	140
5.2.2.	Estimation of Nateglinide (Spectroscopic Method)	140
5.2.3.	Estimation of Glipizide (HPLC Method)	140
5.2.3.1.	Optimization of Chromatographic Conditions	140
5.2.3.1.1.	Effect of Mobile Phase pH	140
5.2.3.1.2.	Effect of Mobile Phase Composition	143
5.2.3.1.3.	Effect of Mobile Phase flow rate	145
5.2.3.2.	Proposed Chromatographic Method	145
5.2.3.3.	Validation of the Proposed Method	146
5.2.3.3.1.	Calibration Curve (Linearity)	146
5.2.3.3.2.	Accuracy and Precision	147
5.2.3.3.3.	Sensitivity	148
5.2.3.3.4.	Selectivity	149
5.2.3.3.5.	Stability	149
5.2.3.3.6.	Extraction efficiency	149
5.2.3.4.	Pharmacokinetic Analysis of Glipizide from Rabbits	149
5.2.4.	Estimation of Nateglinide (HPLC Method)	152
5.2.4.1.	Optimization of Chromatographic Conditions	152
5.2.4.1.1.	Effect of Mobile Phase pH	152
5.2.4.1.2.	Effect of Mobile Phase Composition	155
5.2.4.1.3.	Effect of Mobile Phase Flow Rate	155
5.2.4.2.	Proposed Chromatographic Method	156
5.2.4.3.	Validation of the Proposed Method	158
5.2.4.3.1.	Calibration Curve (Linearity)	158
5.2.4.3.2.	Accuracy and Precision	159
5.2.4.3.3.	Sensitivity	160
5.2.4.3.4.	Specificity	160
5.2.4.3.5.	Stability	161
5.2.4.3.6.	Extraction Efficiency	161
5.2.4.3.7.	System Suitability	161
5.2.4.4.	Pharmacokinetic Analysis of Nateglinide from Rabbits	162
5.3.	References	163
6.	**Glipizide Matrices**	**165**
6.1.	HPMC-MCC-Starch Matrices	165
6.1.1.	In Vitro Dissolution & Release Kinetic Studies	165
6.1.1.1.	3^2 Full factorial Experimental Design	176
6.1.2.	Characterization of Optimized Formulations	181
6.1.2.1.	Release Mechanism by Kopcha Model	182
6.1.2.2.	Swelling Study	183

6.1.2.3.	SEM Study	184
6.2.	MCC-Alginate & MCC-Glyceryl Behenate Matrices	187
6.2.1.	In Vitro Dissolution & Release Kinetic Studies	187
6.3.	EC- HPMC, Guar Gum & Xanthan gum Matrices	191
6.3.1.	In Vitro Dissolution & Release Kinetic Studies	191
6.3.2.	Characterization of Optimized Formulations	199
6.3.2.1.	Release Mechanism by Kopcha Model	199
6.3.2.2.	Swelling Study	199
6.3.2.3.	SEM Study	201
6.4.	Carbopol Matrices	204
6.4.1.	In Vitro Dissolution & Release Kinetic Studies	204
6.4.2.	Characterization of Optimized Formulations	211
6.4.2.1.	Release Mechanism by Kopcha Model	211
6.4.2.2.	SEM Study	212
6.5.	Carrageenan Matrices	213
6.5.1.	In Vitro Dissolution & Release Kinetic Studies	213
6.6.	Eudragit Matrices	218
6.6.1.	In Vitro Dissolution & Release Kinetic Studies	218
6.6.2.	Characterization of Optimized Formulations	222
6.6.2.1.	Release Mechanism by Kopcha Model	222
6.6.2.2.	Swelling Study	222
6.6.2.3.	SEM Study	224
6.7.	Sodium Alginate Matrices	227
6.8.	Stability Studies	231
6.9.	References	232
7.	**Nateglinide Matrices**	**237**
7.1.	HPMC-MCC-Starch Matrices	237
7.1.1.	In Vitro Dissolution & Release Kinetic Studies	237
7.1.2.	Characterization of Optimized Formulations	242
7.1.2.1.	Release Mechanism by Kopcha Model	242
7.1.2.2.	Swelling Study	243
7.1.2.3.	SEM Study	244
7.2.	Ethyl Cellulose & Carbopol Matrices	247
7.2.1.	In Vitro Dissolution & Release Kinetic Studies	247
7.2.2.	Characterization of Optimized Formulations	251
7.2.2.1.	Release Mechanism by Kopcha Model	251
7.2.2.2.	Swelling Study	252
7.2.2.3.	SEM Study	256
7.3.	Xanthan Gum Matrices	259
7.3.1.	In Vitro Dissolution & Release Kinetic Studies	259
7.3.2.	Characterization of Optimized Formulations	262
7.3.2.1.	Release Mechanism by Kopcha Model	262
7.3.2.2.	SEM Study	263
7.4.	Alginate-Chitosan and Eudragit-HPMC Matrices	264
7.4.1.	In Vitro Dissolution & Release Kinetic Studies	264
7.4.2.	Characterization of Optimized Formulations	267
7.4.2.1.	Release Mechanism by Kopcha Model	267
7.4.2.2.	Swelling Study	268

7.4.2.3.	SEM Study	270
7.5.	Stability Studies	270
7.6.	References	272
8.	**In Vivo Study**	**273**
8.1.	Pharmacokinetic study of M-3 Matrices	273
8.1.1.	Drug Absorption Study in Rabbits and Pharmacokinetic Analysis	273
8.1.2.	Establishment of IVIVC	275
8.1.3.	Internal Validation of IVIVC	276
8.2.	Pharmacokinetic study of Glytop-2.5 SR, M-25, M-75 and M-120 Matrices	276
8.3.	Pharmacokinetic study of Natelide-60, J-11 and J-21 Matrices	282
8.4.	References	285

Section IV Conclusions

9.	**Conclusions**	**287**